Medi Caps Ltd Stock Price Today (NSE: MEDICAPQ)
Fundamental Score
Medi Caps Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Medi Caps Ltd share price today is ₹23.20, down 3.17% on NSE/BSE as of 30 March 2026. Medi Caps Ltd (MEDICAPQ) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹41.96 (Cr). The 52-week high for MEDICAPQ share price is ₹47.20 and the 52-week low is ₹21.00. The company has a Return on Equity (ROE) of -1.94% and a debt-to-equity ratio of 0.00.
Medi Caps Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Medi Caps Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Medi Caps Share Price: A Value Investor's Cautious Perspective
The pharmaceutical sector, while generally defensive, is heavily reliant on continuous research & development and stringent regulatory compliance. Success hinges on innovation and efficient capital allocation. This analysis examines the Medi Caps share price through the lens of a conservative value investor prioritizing capital preservation. Currently trading at ₹24.30, Medi Caps Ltd presents a challenging scenario given its absence of a price-to-earnings (PE) ratio and, more concerningly, a negative Return on Capital Employed (ROCE) of -2.12%.
A negative ROCE indicates that the company is not generating sufficient returns on its invested capital. This is a red flag for a value investor as it signifies potential inefficiencies in operations, excessive debt burden, or a misallocation of resources. While industry peers like
Mankind Pharma Ltd demonstrate robust profitability and effective management, as seen in their consistently positive ROCE and strong earnings growth, Medi Caps appears to be struggling to generate shareholder value. Assessing management quality is crucial; are resources being managed effectively, or are there underlying structural issues hindering performance?The negative ROCE directly impacts the company's economic moat. A strong moat protects a company's profitability from competitors. A negative ROCE suggests that Medi Caps lacks a durable competitive advantage. The company may be facing challenges in pricing its products, managing its costs, or competing effectively in its chosen market segments. This situation warrants a deep dive into the company's cost structure, pricing strategies, and competitive landscape to identify the root causes of the underperformance.
From a value investing perspective focused on safety, the current financial data for Medi Caps Ltd requires extreme caution. This observational analysis is part of a comprehensive 80-parameter fundamental audit verified by Sweta Mishra, emphasizing a rigorous and data-driven approach. Further investigation is needed to understand the long-term viability and potential for future profitability before considering any investment decision.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Medi Caps Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of MEDICAPQ across key market metrics for learning purposes.
Positive Indicators
3 factors identified
Debt-Free Balance Sheet (D/E: 0.00)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Balanced Promoter Holding (50.77%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
8 factors identified
Below-Average Return on Equity (-1.94%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (-2.12%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Profit Decline Concern (-687.10%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Revenue Contraction (-75.63%)
Observation: Sales decline may indicate market challenges or competitive pressures.
Analysis: Negative revenue growth requires analysis of market conditions.
Limited Growth History (-9.96% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.
Weak Interest Coverage (-196.33x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
Limited Institutional Interest (FII+DII: 0.03%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Medi Caps Ltd Financial Statements
Comprehensive financial data for Medi Caps Ltd including income statement, balance sheet and cash flow
About MEDICAPQ (Medi Caps Ltd)
Medi Caps Ltd is a dynamic pharmaceutical company dedicated to advancing healthcare through innovative drug development and manufacturing. With a focus on providing high-quality, a...ffordable medicines, Medi Caps is committed to improving patient outcomes across a range of therapeutic areas. The company’s state-of-the-art facilities adhere to the strictest international regulatory standards, ensuring the safety and efficacy of its products. Medi Caps is actively involved in research and development, constantly seeking new and improved formulations to address unmet medical needs. Their dedication extends beyond product development; they are focused on building strong partnerships with healthcare professionals and distributors to ensure their medications are accessible to those who need them most. Medi Caps operates with a deep commitment to ethical business practices and environmental sustainability. The company strives to minimize its environmental footprint by implementing eco-friendly manufacturing processes and promoting responsible waste management. Furthermore, Medi Caps actively engages with local communities through various initiatives aimed at improving health and well-being. The company believes in fostering a culture of innovation and collaboration, empowering its employees to contribute their expertise and passion to the pursuit of pharmaceutical excellence. They have invested significantly in training and development programs to nurture talent and build a highly skilled workforce capable of driving future growth. Medi Caps Ltd is strategically positioned for continued growth and success in the evolving pharmaceutical landscape. By focusing on innovation, quality, and accessibility, the company is poised to expand its product portfolio and reach new markets. Medi Caps continues to build its brand reputation as a trusted provider of high-quality medications, and is focused on building long-term value for its stakeholders. With a strong leadership team and a dedicated workforce, Medi Caps is well-equipped to meet the challenges and opportunities of the pharmaceutical industry, remaining committed to its mission of improving global health and well-being.
Company Details
Key Leadership
Corporate Events
MEDICAPQ Share Price: Frequently Asked Questions
What is the current share price of Medi Caps Ltd (MEDICAPQ)?
As of 30 Mar 2026, 12:07 pm IST, Medi Caps Ltd share price is ₹23.20. The MEDICAPQ stock has a market capitalisation of ₹41.96 (Cr) on NSE/BSE.
Is MEDICAPQ share price Overvalued or Undervalued?
MEDICAPQ share price is currently trading at a P/E ratio of 0.00x, compared to the industry average of 31.77x. Based on this relative valuation, the Medi Caps Ltd stock appears to be Fairly Valued against its sector peers.
What is the 52-week high and low of MEDICAPQ share price?
The 52-week high of MEDICAPQ share price is ₹47.20 and the 52-week low is ₹21.00. These values are updated daily from NSE/BSE price data.
What factors affect the Medi Caps Ltd share price?
Key factors influencing MEDICAPQ share price include quarterly earnings growth (Sales Growth: -75.63%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Medi Caps Ltd a good stock for long-term investment?
Medi Caps Ltd shows a 5-year Profit Growth of 10.20% and an ROE of -1.94%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.00 before investing in MEDICAPQ shares.
How does Medi Caps Ltd compare with its industry peers?
Medi Caps Ltd competes with major peers in the Pharmaceuticals. Investors should compare MEDICAPQ share price P/E of 0.00x and ROE of -1.94% against the industry averages to determine competitive standing.
What is the P/E ratio of MEDICAPQ and what does it mean?
MEDICAPQ share price has a P/E ratio of N/Ax compared to the industry average of 31.77x. Investors pay ₹N/A for every ₹1 of annual earnings.
How is MEDICAPQ performing according to Bull Run's analysis?
MEDICAPQ has a Bull Run fundamental score of 20.6/100, indicating concerns requiring careful analysis. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does MEDICAPQ belong to?
MEDICAPQ operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Medi Caps Ltd share price.
What is Return on Equity (ROE) and why is it important for MEDICAPQ?
MEDICAPQ has an ROE of -1.94%, which suggests challenges in generating returns from shareholders equity. ROE measures how efficiently Medi Caps Ltd generates profits from shareholders capital.
How is MEDICAPQ debt-to-equity ratio and what does it indicate?
MEDICAPQ has a debt-to-equity ratio of 0.00, which indicates conservative financing with low financial risk.
What is MEDICAPQ dividend yield and is it a good dividend stock?
MEDICAPQ offers a dividend yield of 0.00%, meaning you receive ₹0.00 annual dividend for every ₹100 invested in Medi Caps Ltd shares.
How has MEDICAPQ share price grown over the past 5 years?
MEDICAPQ has achieved 5-year growth rates of: Sales Growth -9.96%, Profit Growth 10.20%, and EPS Growth 10.20%.
What is the promoter holding in MEDICAPQ and why does it matter?
Promoters hold 50.77% of MEDICAPQ shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Medi Caps Ltd.
What is MEDICAPQ market capitalisation category?
MEDICAPQ has a market capitalisation of ₹42 crores, placing it in the Small-cap category.
How volatile is MEDICAPQ stock?
MEDICAPQ has a beta of N/A. A beta > 1 suggests the Medi Caps Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is MEDICAPQ operating profit margin trend?
MEDICAPQ has a 5-year average Operating Profit Margin (OPM) of 11.15%, indicating the company's operational efficiency.
How is MEDICAPQ quarterly performance?
Recent quarterly performance shows Medi Caps Ltd YoY Sales Growth of -75.63% and YoY Profit Growth of -687.10%.
What is the institutional holding pattern in MEDICAPQ?
MEDICAPQ has FII holding of 0.00% and DII holding of 0.03%. Significant institutional holding often suggests professional confidence in the Medi Caps Ltd stock.